Nanomedicine in cancer therapy

Signal Transduction and Targeted Therapy, Journal Year: 2023, Volume and Issue: 8(1)

Published: Aug. 7, 2023

Cancer remains a highly lethal disease in the world. Currently, either conventional cancer therapies or modern immunotherapies are non-tumor-targeted therapeutic approaches that cannot accurately distinguish malignant cells from healthy ones, giving rise to multiple undesired side effects. Recent advances nanotechnology, accompanied by our growing understanding of biology and nano-bio interactions, have led development series nanocarriers, which aim improve efficacy while reducing off-target toxicity encapsulated anticancer agents through tumor tissue-, cell-, organelle-specific targeting. However, vast majority nanocarriers do not possess hierarchical targeting capability, their indices often compromised poor accumulation, inefficient cellular internalization, inaccurate subcellular localization. This Review outlines current prospective strategies design organelle-targeted nanomedicines, highlights latest progress technologies can dynamically integrate these three different stages static maximize outcomes. Finally, we briefly discuss challenges future opportunities for clinical translation nanomedicines.

Language: Английский

---

Biomedical polymers: synthesis, properties, and applications

Science China Chemistry, Journal Year: 2022, Volume and Issue: 65(6), P. 1010 - 1075

Published: April 24, 2022

Language: Английский

---

Electrospun fibers with blank surface and inner drug gradient for improving sustained release

Biomaterials Advances, Journal Year: 2023, Volume and Issue: 150, P. 213404 - 213404

Published: March 31, 2023

Language: Английский

---

Multifunctional Ac@ZIF-8/AgNPs nanoplatform with pH-responsive and ROS scavenging antibacterial properties promotes infected wound healing

Chemical Engineering Journal, Journal Year: 2024, Volume and Issue: 489, P. 151485 - 151485

Published: April 20, 2024

Language: Английский

---

Using the Intranasal Route to Administer Drugs to Treat Neurological and Psychiatric Illnesses: Rationale, Successes, and Future Needs

CNS Drugs, Journal Year: 2022, Volume and Issue: 36(7), P. 739 - 770

Published: June 27, 2022

Language: Английский

---

“Targeting Design” of Nanoparticles in Tumor Therapy

Pharmaceutics, Journal Year: 2022, Volume and Issue: 14(9), P. 1919 - 1919

Published: Sept. 11, 2022

Tumor-targeted therapy based on nanoparticles is a popular research direction in the biomedical field. After decades of and development, both passive targeting ability inherent properties NPs active ligand receptor interaction have gained deeper understanding. Unfortunately, most targeted delivery strategies are still preclinical trial stage, so it necessary to further study biological fate particles vivo mechanism with tumors. This article reviews different NPs, focuses physical chemical (size, morphology, surface intrinsic properties), ligands (binding number/force, activity species) receptors (endocytosis, distribution recycling) other factors that affect particle targeting. The limitations solutions these discussed, variety new schemes introduced, hoping provide guidance for future design achieve purpose rapid transformation into clinical application.

Language: Английский

---

A comprehensive review on peptide-bearing biomaterials: From ex situ to in situ self-assembly

Coordination Chemistry Reviews, Journal Year: 2023, Volume and Issue: 502, P. 215600 - 215600

Published: Dec. 14, 2023

Language: Английский

---

Charge‐Reversible Nanoparticles: Advanced Delivery Systems for Therapy and Diagnosis

Small, Journal Year: 2023, Volume and Issue: 20(3)

Published: Sept. 7, 2023

Abstract The past two decades have witnessed a rapid progress in the development of surface charge‐reversible nanoparticles (NPs) for drug delivery and diagnosis. These NPs are able to elegantly address polycation dilemma. Converting their charge from negative/neutral positive at target site, they can substantially improve drugs diagnostic agents. By specific stimuli like shift pH redox potential, enzymes, or exogenous such as light heat, reversal NP be achieved site. activated enhances adhesion cells facilitates cellular uptake, endosomal escape, mitochondrial targeting. Because these properties, efficacy incorporated well sensitivity agents essentially enhanced. Furthermore, shown overcome biofilm formed by pathogenic bacteria shuttle antibiotics directly cell membrane microorganisms. In this review, up‐to‐date design emerging applications diagnosis highlighted.

Language: Английский

---

Metalloporphyrin MOFs‐Based Nanoagent Enabling Tumor Microenvironment Responsive Sonodynamic Therapy of Intracranial Glioma Signaled by NIR‐IIb Luminescence Imaging

Advanced Functional Materials, Journal Year: 2023, Volume and Issue: 34(3)

Published: Oct. 5, 2023

Abstract Noninvasive sonodynamic therapy (SDT) shows promise for brain glioma treatment due to deep tissue‐penetrating capabilities (>10 cm) of ultrasound and high spatial resolutions. Yet, this technique is hindered by inefficient production reactive oxygen species (ROS), resulting from the hypoxic tumor microenvironment (TME), level ROS scavenger glutathione (GSH), inability visualize in vivo precise management monitoring current sonosentizers. To address these challenges, we fabricated a core‐shell heterostructure sonosensitizer (labeled as DFM), which meso‐tetra (4‐carboxyphenyl) porphine (TCPP) porphyrin metal‐organic frameworks (MOF, PCN‐224(Fe)) serve porous shell contain approved chemotherapeutics sorafenib (SRF) effectively inhibit GSH synthesis, while NaErF 4 :Yb@NaLuF nanoparticles core provide TME‐responsive NIR IIb (≈1500–1800 nm) luminescence at 1525 optical imaging. Coordination Fe 3+ into macrocycle TCPP MOFs found to, besides triggering ferroptosis, reduce phosphorescence (23% decrease) increase triplet state ( T 1 ) quenching, substantially promoting singlet generation (2.6‐fold increase). Furthermore, TME facilitates reduction 2+ , thereby eliminating quenching augmenting Er (5‐fold increase) nanoagents accumulation imaging intracranial glioma, realizing dynamical SDT processes. Compared control groups, vitro experiments confirm effective results 6‐fold volume gliomas, reaching survival rate 80% 30 days posttreatment.

Language: Английский

---

Enhancing Methotrexate Delivery in the Brain by Mesoporous Silica Nanoparticles Functionalized with Cell-Penetrating Peptide using in Vivo and ex Vivo Monitoring

Molecular Pharmaceutics, Journal Year: 2023, Volume and Issue: 20(3), P. 1531 - 1548

Published: Feb. 10, 2023

The blood–brain barrier (BBB) acts as a physical/biochemical that protects brain parenchyma from potential hazards exerted by different xenobiotics found in the systemic circulation. This is created "a lipophilic gate" well series of highly organized influx/efflux mechanisms. BBB bottleneck adversely affects efficacy chemotherapeutic agents treating CNS malignancies such glioblastoma, an aggressive type cancer affecting brain. In present study, mesoporous silica nanoparticles (MSNs) were conjugated with transactivator transcription (TAT) peptide, cell-penetrating to produce MSN-NH-TAT aim improving methotrexate (MTX) penetration into TAT-modified nanosystem was characterized Fourier transform infrared spectrometry (FTIR), field emission scanning electron microscopy (FE-SEM), transmission (TEM), atomic force (AFM), dynamic light scattering (DLS), and N2 adsorption–desorption analysis. vitro hemolysis cell viability studies confirmed biocompatibility MSN-based nanocarriers. addition, vivo showed MTX-loaded improved brain-to-plasma concentration ratio, uptake clearance, drug's blood terminal half-life, compared use free MTX. Taken together, results study indicate MSN functionalization TAT crucial for delivery MTX represents promising alternative drug carrier deliver via overcoming BBB.

Language: Английский

---